Equities

Venus Remedies Ltd

VENUSREM:NSI

Venus Remedies Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (INR)342.10
  • Today's Change-1.90 / -0.55%
  • Shares traded18.30k
  • 1 Year change+46.20%
  • Beta1.8722
Data delayed at least 15 minutes, as of Sep 20 2024 11:11 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Venus Remedies Ltd is a research-driven pharmaceutical company. The Company is a global injectable manufacturer. It manufactures products catering to critical care segments such as antimicrobial resistance, anti-cancer, Anti-infective, Neurology, Skin and Wound Care, and Pain Management. With a diverse portfolio of innovative and high-quality products, the Company is dedicated to revolutionizing patient care through its specialized therapeutic segments such as anti-infective (antibiotics), oncology, neurology, pain management, and skin & wound care. The Company operates only in one business segment: Pharmaceutical Formulation and is engaged in manufacturing and trading of medicines. Its focus therapy areas include medicine, surgery, neuro and orthopedics. The Company’s brands include Potentox, Vancoplus Combi, Tobracef, Supime, Zydotum, Neurotol, Trois, Septiloc, Mucomelt, and others. It has three manufacturing facilities: Panchkula and Baddi in India and Werne in Germany.

  • Revenue in INR (TTM)6.15bn
  • Net income in INR285.31m
  • Incorporated1989
  • Employees1.19k
  • Location
    Venus Remedies Ltd51-52, Industrial Area, Phase-1PANCHKULA 134113IndiaIND
  • Phone+91 1 722933090
  • Fax+91 1 722565566
  • Websitehttps://www.venusremedies.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Brooks Laboratories Ltd817.15m-175.35m3.95bn293.00------4.83-6.84-6.8431.86--------2,788,911.00---13.86---22.9029.0926.19-21.46-27.47--0.0861----25.767.636.26---12.73--
Medico Remedies Ltd1.44bn85.50m3.98bn193.0047.25--34.742.761.021.0217.15--------7,474,037.00--6.15--12.4025.0725.265.933.99--12.49----3.198.2114.4939.49-7.58--
SMS Lifesciences India Ltd3.24bn178.73m4.50bn574.0025.19--13.991.3959.1059.101,070.58--------5,642,058.00--4.08--6.7334.8229.685.334.46--2.88--2.61-3.04-4.13-20.68-12.62-3.090.00
Venus Remedies Ltd.6.15bn285.31m4.59bn1.19k16.08--8.600.746721.3721.37461.21--------5,180,368.00--4.82--6.1740.7438.904.645.58--662.71----8.2713.327.25--6.38--
Lyka Labs Ltd1.18bn7.97m5.26bn423.00807.27--45.004.440.18260.182635.62--------2,799,802.00---5.48---8.3060.4560.820.5065-9.16--1.36----19.479.4581.16--13.88--
ZIM Laboratories Ltd3.82bn179.18m5.33bn556.0029.82--15.331.403.673.6777.81--------6,867,013.00--3.88--6.5453.7647.454.693.97--3.44--1.21-7.801.84-29.422.3729.41--
Medicamen Biotech Ltd1.80bn81.05m5.65bn378.0055.08--41.833.138.118.11160.31--------4,772,797.00--5.89--8.4546.8936.543.529.58--2.79--8.4627.297.90-26.36-1.89-16.710.00
Accent Microcell Ltd2.45bn301.68m5.77bn174.0014.673.5216.672.3518.6718.67126.4577.86------14,109,070.00--------31.00--12.29--3.42--0.0724--24.45--146.63------
Data as of Sep 20 2024. Currency figures normalised to Venus Remedies Ltd's reporting currency: Indian Rupee INR
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.